Amgen Inc. (4332.HK)

1,761.000 +1,761.000 (-4.81%) At close: 09:20AM HKT

Amgen Inc.

One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
https://www.amgen.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 25,200

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Robert A. Bradway	Chairman, CEO & President	42.88M	N/A	1963
Mr. Peter H. Griffith	Executive VP & CFO	20.12M	N/A	1959
Mr. Esteban Santos	Executive Vice President of Operations	19.71M	N/A	1968
Dr. David M. Reese M.D.	Executive Vice President of Research & Development	22.14M	N/A	1963
Mr. Murdo Gordon	Executive VP of Global Commercial Operations	21.24M	N/A	1967
Mr. Matthew C. Busch	Chief Accounting Officer & VP of Finance	N/A	N/A	1974
Mr. Mike Zahigian	Senior VP & Chief Information Officer	N/A	N/A	N/A
Mr. Arvind Sood	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Jonathan P. Graham	Executive VP, General Counsel & Secretary	19.07M	N/A	1961
Ms. Nancy A. Grygiel	Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer	N/A	N/A	1968

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Corporate governance

Amgen Inc.’s ISS governance QualityScore as of 1 November 2023 is 3. The pillar scores are Audit: 4; Board: 9; Shareholder rights: 1; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.